Abstract 1908P
Background
To refine future physical activity guidelines for cancer survivors, that have remained mostly generic until now, we performed an umbrella review of meta-analyses for physical activity in survivors of any cancer type and for every studied outcome in the literature.
Methods
We searched the Medline and Scopus databases in August 2023. Meta-analyses showing nominally statistically significant associations were categorized into four evidence groups: strong, highly suggestive, suggestive, and weak.
Results
In total, 101 publications reporting 740 meta-analytic comparisons were included. Notably, 427 meta-analyses pertained to breast, 104 to prostate, 58 to hematological, 79 to colorectal and 54 to lung cancer survivors. Overall, 16 associations were judged to provide strong evidence and 10 highly suggestive evidence, while 93 suggestive evidence. In breast cancer survivors, there was strong and highly suggestive evidence that post-diagnosis physical activity is associated with lower all-cause mortality, recurrence, cancer-related fatigue, depression, and better mental health, body strength, aerobic capacity, and weight loss. In prostate cancer survivors, strong evidence was identified for the positive association of post-diagnosis physical activity with cardiovascular fitness, cancer-specific quality of life and fatigue amelioration. In colorectal cancer survivors, strong and highly suggestive evidence supported the association of post-diagnosis physical activity and post-diagnosis recreational physical activity with lower all-cause mortality. In lung cancer survivors, strong evidence supported the association of preoperative exercise for reduction of patients’ hospital length of stay. Suggestive evidence was identified linking post-diagnosis physical activity with ameliorating further medical, quality of life and strength outcomes for breast, prostate, lung, colorectal, head and neck, hematological and childhood cancers.
Conclusions
This grading of the entirety of the available evidence can further facilitate robust introduction of targeted exercise prescription by cancer type and for specific outcomes in oncology care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1717TiP - CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
Presenter: Laurence Albiges
Session: Poster session 12
1822P - Incidence of cachexia and health resource use (HRU) in patients with breast, colorectal, lung, pancreatic, and prostate cancers
Presenter: Imran Ali
Session: Poster session 12
1823P - Significance of skeletal muscle measurement in cancer-associated cachexia screening
Presenter: Lynn Gottmann
Session: Poster session 12
1824P - Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates
Presenter: Filippo Dall'Olio
Session: Poster session 12
1826P - Risk factors and incidence of osteoporosis in patients with breast cancer according to gender
Presenter: Chang Ik Yoon
Session: Poster session 12
1827P - Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies
Presenter: Maria Concetta Cursano
Session: Poster session 12
1828P - A cross-sectional study investigating the current diagnostic & therapeutical approaches to bone metastases (BoM) in patients (pts) with non-small cell lung cancer (NSCLC)
Presenter: Sara Pilotto
Session: Poster session 12
1829P - Nutritional status assessment for patients with common cancer in a cancer hospital of southwest China
Presenter: Huiqing Yu
Session: Poster session 12
Resources:
Abstract
1830P - Comprehensive prognostic effects of inflammatory and nutritional markers to predict survival in women with breast cancer
Presenter: Susanna Hutajulu
Session: Poster session 12
1831P - Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma
Presenter: Anthony Tarabay
Session: Poster session 12